Deck Bio Launches Multi-Target T Cell Engager Platform for Solid Tumors, With Preclinical Data to be Presented at AACR 2026

B Emerging biotechnology company advancing multi-pMHC targeted T cell engagers to address tumor heterogeneity and resistance Differentiated approach integrates proprietary T cell receptor (TCR) specificity…
posteditor
posteditor
Articles: 16137

Other News